TY - JOUR
T1 - The scleroderma patient-centered intervention network cohort
T2 - Baseline clinical features and comparison with other large scleroderma cohorts
AU - SPIN Investigators
AU - Dougherty, Dane H.
AU - Kwakkenbos, Linda
AU - Carrier, Marie Eve
AU - Salazar, Gloria
AU - Assassi, Shervin
AU - Baron, Murray
AU - Bartlett, Susan J.
AU - Furst, Daniel E.
AU - Gottesman, Karen
AU - Van Den Hoogen, Frank
AU - Malcarne, Vanessa L.
AU - Mouthon, Luc
AU - Nielson, Warren R.
AU - Poiraudeau, Serge
AU - Sauvé, Maureen
AU - Boire, Gilles
AU - Bruns, Alessandra
AU - Chung, Lorinda
AU - Denton, Christopher
AU - Dunne, James V.
AU - Fortin, Paul
AU - Frech, Tracy
AU - Gill, Anna
AU - Gordon, Jessica
AU - Herrick, Ariane L.
AU - Hinchcliff, Monique
AU - Hudson, Marie
AU - Johnson, Sindhu R.
AU - Jones, Niall
AU - Kafaja, Suzanne
AU - Larché, Maggie
AU - Manning, Joanne
AU - Pope, Janet
AU - Spiera, Robert
AU - Steen, Virginia
AU - Sutton, Evelyn
AU - Thorne, Carter
AU - Wilcox, Pearce
AU - Thombs, Brett D.
AU - Mayes, Maureen D.
AU - Albert, Alexandra
AU - Arsenault, Guylaine
AU - Bissonette, Lyne
AU - Boutron, Isabelle
AU - Carreira, Patricia
AU - Maia, Angela Costa
AU - Dagenais, Pierre
AU - Domsic, Robyn
AU - El-Baalbaki, Ghassan
AU - Harel, Daphna
N1 - Publisher Copyright:
© The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Objectives. The Scleroderma Patient-centered Intervention Network (SPIN) Cohort is a web-based cohort designed to collect patient-reported outcomes at regular intervals as a framework for conducting trials of psychosocial, educational, self-management and rehabilitation interventions for patients with SSc. The aim of this study was to present baseline demographic, medical and patient-reported outcome data of the SPIN Cohort and to compare it with other large SSc cohorts. Methods. Descriptive statistics were used to summarize SPIN Cohort characteristics; these were compared with published data of the European Scleroderma Trials and Research (EUSTAR) and Canadian Scleroderma Research Group (CSRG) cohorts. Results. Demographic, organ involvement and antibody profile data for SPIN (N = 1125) were generally comparable with that of the EUSTAR (N = 7319) and CSRG (N = 1390) cohorts. There was a high proportion of women and White patients in all cohorts, though relative proportions differed. Scl70 antibody frequency was highest in EUSTAR, somewhat lower in SPIN, and lowest in CSRG, consistent with the higher proportion of interstitial lung disease among dcSSc patients in SPIN compared with in CSRG (48.5 vs 40.3%). RNA polymerase III antibody frequency was highest in SPIN and remarkably lower in EUSTAR (21.1 vs 2.4%), in line with the higher prevalence of SSc renal crisis (4.5 vs 2.1%) in SPIN. Conclusion. Although there are some differences, the SPIN Cohort is broadly comparable with other large prevalent SSc cohorts, increasing confidence that insights gained from the SPIN Cohort should be generalizable, although it should be noted that all three cohorts include primarily White participants.
AB - Objectives. The Scleroderma Patient-centered Intervention Network (SPIN) Cohort is a web-based cohort designed to collect patient-reported outcomes at regular intervals as a framework for conducting trials of psychosocial, educational, self-management and rehabilitation interventions for patients with SSc. The aim of this study was to present baseline demographic, medical and patient-reported outcome data of the SPIN Cohort and to compare it with other large SSc cohorts. Methods. Descriptive statistics were used to summarize SPIN Cohort characteristics; these were compared with published data of the European Scleroderma Trials and Research (EUSTAR) and Canadian Scleroderma Research Group (CSRG) cohorts. Results. Demographic, organ involvement and antibody profile data for SPIN (N = 1125) were generally comparable with that of the EUSTAR (N = 7319) and CSRG (N = 1390) cohorts. There was a high proportion of women and White patients in all cohorts, though relative proportions differed. Scl70 antibody frequency was highest in EUSTAR, somewhat lower in SPIN, and lowest in CSRG, consistent with the higher proportion of interstitial lung disease among dcSSc patients in SPIN compared with in CSRG (48.5 vs 40.3%). RNA polymerase III antibody frequency was highest in SPIN and remarkably lower in EUSTAR (21.1 vs 2.4%), in line with the higher prevalence of SSc renal crisis (4.5 vs 2.1%) in SPIN. Conclusion. Although there are some differences, the SPIN Cohort is broadly comparable with other large prevalent SSc cohorts, increasing confidence that insights gained from the SPIN Cohort should be generalizable, although it should be noted that all three cohorts include primarily White participants.
KW - Cohort
KW - Scleroderma
KW - Systemic scleroderma
KW - Systemic sclerosis
UR - http://www.scopus.com/inward/record.url?scp=85052607430&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052607430&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/key139
DO - 10.1093/rheumatology/key139
M3 - Article
C2 - 29868924
AN - SCOPUS:85052607430
SN - 1462-0324
VL - 57
SP - 1623
EP - 1631
JO - Rheumatology (United Kingdom)
JF - Rheumatology (United Kingdom)
IS - 9
ER -